Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories

18:46 EDT 23rd October 2017 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 1–25 of 8,300+

Relevant

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC. ...


Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders. Amylon […] The post ProQ...


Summit Therapeutics PLC (SMMT) and Orexigen Therapeutics (OREX) Head to Head Review

Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitabiliy, analyst recommendations, earnings, valuation and risk. Summit Therapeutics PLC has higher revenue, but lower earnings than Orexigen Therapeutics.

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics today announced the company has relaunched as Translate Bio (www.translate.bio). The new name stems from the company’s focus on pioneering the translation of RNA science into therapeutics promoting hea...

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat […]The post CRISPR Therapeutics and Neon T...

Realm Therapeutics to Present at the 2017 BIO Investor Forum

MALVERN, PA -- (Marketwired) -- 10/16/17 -- Realm Therapeutics PLC (AIM: RLM) (AIM: RLM) Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company") Realm Therapeutics to Present at th...

Dragonfly Therapeutics names world leader in NK therapeutics as CSO

Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO).

Head-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers

Anika Therapeutics is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it compare to its competitors? We will compare Anika Therapeutics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation. Anika Therapeutics' competitors have higher revenue and earnings than Anik...

Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio

GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's...   

Probably Relevant

Acer Therapeutics receives $15.7mm investment

Acer Therapeutics Inc. (rare disease therapeutics) received $15.7mm (includes $5.7mm in conversion of convertible notes) from...

Bone Therapeutics SA : Publie son rapport d’activité du T1 2017

Bone Therapeutics SA — Thursday, August 24th 2017 at 5:01am UTC Bone Therapeutics publiera ses résultats semestriels, le 31 août 2017 Gosselies, Belgique, le 24 août 2017, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris: BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux non satisfaits dans les domaines de l’orthopé...

Cingulate Therapeutics to Present at 2017 Biotechnology Innovation Organization International ...

About Cingulate Therapeutics Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the Read more...

CRISPR Therapeutics, Neon Therapeutics partner to develop new T-cell therapies

A research collaboration was announced by CRISPR Therapeutics and Neon Therapeutics to cultivate new T-cell therapies using g -More- 

Immune-Onc Therapeutics Awarded "Buzz of BIO"

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a new biopharmaceutical company focused on advancing immuno-oncology therapeutics, announced that the Biotechnology Innovation Organization (BIO) has named the Company "

Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase

WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that its...

M&As this week: BriaCell Therapeutics, Lentigen Technology

BriaCell Therapeutics plans to acquire Sapientia Pharmaceuticals through its subsidiary BriaCell Therapeutics (BriaCell USA).

Opexa Therapeutics, Inc.: Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement

Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need Conc...

CSE: 2017-1012 - Delist - Pivotal Therapeutics Inc. (PVO)

TORONTO, ONTARIO -- (Marketwired) -- 10/23/17 -- The common shares of Pivotal Therapeutics Inc. will be delisted at the market close today, October 23, 2017. Pivotal Therapeutics is currently susp...

Research Analysts Offer Predictions for United Therapeutics...

United Therapeutics Co. - Equities researchers at Jefferies Group lifted their Q3 2017 earnings estimates for United Therapeutics in a research report issued on Thursday.

RaNA Therapeutics relaunches as Translate Bio

RaNA Therapeutics has relaunched as Translate Bio (www.translate.bio). The new name stems from the company’s focus on pioneering the translation of RNA science into therapeutics promoting healthy gene expression for people living with debilitating genetic diseases. In addition to its new name, the company also announced the recent leadership appointments of Michael Heartlein, Ph.D., as […]...

Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial

WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that it...

Flagship Pioneering launches Sigilon Therapeutics

Flagship Pioneering, a fully-integrated life science innovation enterprise, announced the launch of Sigilon Therapeutics. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer technology, a new clas...

Bone Therapeutics SA : Renforce son Conseil d’administration

Bone Therapeutics SA — Monday, July 3rd 2017 at 5:00am UTC Bone Therapeutics renforce son Conseil d’administration Steve Swinson est élu Président du Conseil d’administration de Bone Therapeutics Dirk Dembski, nommé en qualité d’administrateur indépendant, apporte au Conseil une expertise complémentaire en orthopédie et biotechnologie Michel Helbig continuera à sié...

Rubius Therapeutics raises $120m to advance red blood cell technology

Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing.


Quick Search
Advertisement
 

News Quicklinks